Curbside Consultation in IBD: 49 Clinical Questions, Second Edition

David T Rubin, MD; Sonia Friedman, MD; Francis A Farraye, MD MSc

Question 44: What Is The Risk Of Lymphoma With Antimetabolites And Anti-Tumor Necrosis Factor Agents? (continued)

Peter Irving, MD

Over the past two decades, the treatment of inflammatory bowel disease (IBD) has undergone a paradigm shift. Whereas previous treatment was largely reactive, with drugs being used in response to symptoms, current treatment aims require a much more aggressive approach in an attempt to alter the natural history of the disease. Accordingly, the use of immunomodulating drugs has increased rapidly and it is therefore unsurprising that this has resulted in an increase in treatment-related morbidity. Of the multitude of adverse events that can occur in association with drugs used in the management…